Basics |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
|
IPO Date: |
July 24, 2013 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$2.48B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.22 | 2.54%
|
Avg Daily Range (30 D): |
$0.56 | 1.44%
|
Avg Daily Range (90 D): |
$0.78 | 2.12%
|
Institutional Daily Volume |
Avg Daily Volume: |
.53M |
Avg Daily Volume (30 D): |
.43M |
Avg Daily Volume (90 D): |
.57M |
Trade Size |
Avg Trade Size (Sh.): |
74 |
Avg Trade Size (Sh.) (30 D): |
45 |
Avg Trade Size (Sh.) (90 D): |
50 |
Institutional Trades |
Total Inst.Trades: |
5,891 |
Avg Inst. Trade: |
$2.34M |
Avg Inst. Trade (30 D): |
$2.52M |
Avg Inst. Trade (90 D): |
$2.38M |
Avg Inst. Trade Volume: |
.05M |
Avg Inst. Trades (Per Day): |
2 |
Market Closing Trades |
Avg Closing Trade: |
$3.2M |
Avg Closing Trade (30 D): |
$4.08M |
Avg Closing Trade (90 D): |
$3.94M |
Avg Closing Volume: |
77.41K |
|
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
$11.45
|
$-1.93
|
$-1.55
|
Diluted EPS
|
$11
|
$-1.93
|
$-1.55
|
Revenue
|
$ 40.88M
|
$ 12.46M
|
$ 8.73M
|
Gross Profit
|
$ 36.05M
|
$ 10.75M
|
$ 7.64M
|
Net Income / Loss
|
$ 650.08M
|
$ -112.02M
|
$ -89.29M
|
Operating Income / Loss
|
$ -461.53M
|
$ -127.06M
|
$ -106.63M
|
Cost of Revenue
|
$ 4.83M
|
$ 1.7M
|
$ 1.09M
|
Net Cash Flow
|
$ -3.65M
|
$ 1.91M
|
$ 2.72M
|
PE Ratio
|
3.79
|
|
|
|
|
|